Click here to view French version of this release PathoQuest, a biotechnology company spun out from Institut Pasteur, announced today the on-line publication of results from the PATHOQUEST-1 study. The full manuscript, titled "Untargeted next-generation...

Laboratoire CERBA and PATHOQUEST announced today the signing of a licensing agreement for the iDTECT™ Blood test for use in the precision diagnosis of infectious diseases. Click here to view French version of this release iDTECT™ Blood is a metagenomic test developed...

iDTECT™ Blood is the first NGS-based metagenomics test to be CE-IVD marked for the clinical identification of pathogens from blood samples Click here to view French version of this release PathoQuest, a biotechnology company spun out from Institut Pasteur, today...

Company adds experienced executives to accelerate innovation and growth of their proprietary next generation sequencing (NGS) based solutions for Viral Safety Testing and clinical diagnostic of blood-based infections. Click here to view French version of this release...

This preferred partnership agreement will provide Charles River customers access to PathoQuest’s NGS-based testing solution, which can identify viral contaminants in biological products via a single comprehensive test, overcoming limitations of current viral safety...

PathoQuest today announced new leadership at the Board of directors effective immediately. The shareholders have appointed Benedikt von Braunmühl as Chairman of the Board of Directors. This announcement follows the appointment of Jean-François Brepson as President...

PathoQuest today announced changes to the executive leadership team effective immediately. Jean-François Brepson is appointed by the board as President & Chief Executive Officer. This announcement follows the resignation for personal reasons of Guy-Charles de la...